Drug news
US court rules that Seroquel XR patent (AstraZeneca) is valid
A US court has ruled that the formulation patent for the extended-release version of the antipsychotic Seroquel XR is valid and has been been infringed by generics companies.
The district court in New Jersey has found the formulation patent protecting Seroquel XR (quetiapine fumarate) extended-release tablets to be valid and ruled that four firms - Anchen Pharmaceuticals, Osmotica Pharmaceutical Corp, Torrent and Mylan have infringed it. The formulation patent expires in November 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins